Certain Aspects of Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Sergei Vasil’evich Gritsaev, A.A. Kuzyaeva, S.S. Bessmel’tsev,

DOI:

https://doi.org/10.21320/2500-2139-2017-10-1-7-12

The review dwells on certain problems of mobilization and conditioning regimens, as well as autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with multiple myeloma. The aim of the review is to determine new approaches to improve the effectiveness of the auto-HSCT.

  • Sergei Vasil’evich Gritsaev Russian Scientific Research Institute of Hematology and Transfusiology under the Federal Medico-Biological Agency, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 ; ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии ФМБА», 2-я Советская ул., д. 16, Санкт-Петербург, Российская Федерация, 191024
  • A.A. Kuzyaeva Russian Scientific Research Institute of Hematology and Transfusiology under the Federal Medico-Biological Agency, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 ; ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии ФМБА», 2-я Советская ул., д. 16, Санкт-Петербург, Российская Федерация, 191024
  • S.S. Bessmel’tsev Russian Scientific Research Institute of Hematology and Transfusiology under the Federal Medico-Biological Agency, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 ; ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии ФМБА», 2-я Советская ул., д. 16, Санкт-Петербург, Российская Федерация, 191024
  1. Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома: руководство для врачей. М.: МК, 2016. 504 с.
  2. [Bessmel’tsev SS, Abdulkadyrov KM. Mnozhestvennaya mieloma: rukovodstvo dlya vrachei. (Multiple myeloma: manual for physicians.) Moscow: MK Publ.; 2016. 504 p. (In Russ)]
  3. Менделеева Л.П., Вотякова О.М., Покровская О.С. и др. Национальные рекомендации по диагностике и лечению множественной миеломы. Гематология и трансфузиология. 2014;1(Приложение № 3):1–24.
  4. [Mendeleeva LP, Votyakova OM, Pokrovskaya OS, et al. National guidelines for diagnosis and treatment of multiple myeloma. Gematologiya i transfuziologiya. 2014;1(Suppl 3):1–24. (In Russ)]
  5. Reece DE. Management of multiple myeloma: The changing landscape. Blood Rev. 2007;21(6):301–14. doi: 10.1016/j.blre.2007.07.001. DOI: https://doi.org/10.1016/j.blre.2007.07.001
  6. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25(17):2434–41. doi: 10.1200/jco.2006.10.2509. DOI: https://doi.org/10.1200/JCO.2006.10.2509
  7. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495–502. doi: 10.1056/nejmoa032290. DOI: https://doi.org/10.1056/NEJMoa032290
  8. Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29(12):967–72. doi: 10.1038/sj.bmt.1703575. DOI: https://doi.org/10.1038/sj.bmt.1703575
  9. Michaelis LC, Saad A, Zhong X, et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013;19(5):760–6. doi: 10.1016/j.bbmt.2013.01.004. DOI: https://doi.org/10.1016/j.bbmt.2013.01.004
  10. Cook G, Williams C, Brown JM, et al. High dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(14):874–85. doi: 10.1016/s1470-2045(14)70245-1. DOI: https://doi.org/10.1016/S1470-2045(14)70245-1
  11. Musto P, Simeon V, Grossi A, et al. Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie Ematologiche dell’Adulto Multiple Myeloma Working Party study. Stem Cell Res Ther. 2015;6:64. doi: 10.1186/s13287-015-0033-1. DOI: https://doi.org/10.1186/s13287-015-0033-1
  12. Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of “poor mobilizer” in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant. 2012;47(3):342–51. doi: 10.1038/bmt.2011.82. DOI: https://doi.org/10.1038/bmt.2011.82
  13. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118(17):4530–40. doi: 10.1182/blood-2011-06-318220. DOI: https://doi.org/10.1182/blood-2011-06-318220
  14. Gertz MA. Current status of stem cell mobilization. Br J Haematol. 2010;150(6):647–62. doi: 10.1111/j.1365-2141.2010.08313.x. DOI: https://doi.org/10.1111/j.1365-2141.2010.08313.x
  15. Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15(6):718–23. doi: 10.1016/j.bbmt.2009.02.011. DOI: https://doi.org/10.1016/j.bbmt.2009.02.011
  16. Mazumder A, Kaufman J., Niesvizky R, et al. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients (letter). Leukemia. 2008;22(60):1280–1. doi: 10.1038/sj.leu.2405035. DOI: https://doi.org/10.1038/sj.leu.2405035
  17. Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295–308. doi: 10.1016/j.bbmt.2013.10.013. DOI: https://doi.org/10.1016/j.bbmt.2013.10.013
  18. Duong HK, Savani BN, Copelan E, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014;20(9):1262–73. doi: 10.1016/j.bbmt.2014.05.003. DOI: https://doi.org/10.1016/j.bbmt.2014.05.003
  19. Sung AD, Grima DT, Bernard LM, et al. Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. Bone Marrow Transplant. 2013;48(11):1444–9. doi: 10.1038/bmt.2013.80. DOI: https://doi.org/10.1038/bmt.2013.80
  20. Gertz MA, Kumar SK, Lacy MQ, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2009;43(8):619–25. doi: 10.1038/bmt.2008.369. DOI: https://doi.org/10.1038/bmt.2008.369
  21. Arora M, Burns LJ, Barker JN, et al. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2004;10(6):395–404. doi: 10.1016/s1083-8791(04)00068-0. DOI: https://doi.org/10.1016/S1083-8791(04)00068-0
  22. Nakasone H, Kanda Y, Ueda T, et al. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma. Am J Hematol. 2009;84(12):809–14. doi: 10.1002/ajh.21552. DOI: https://doi.org/10.1002/ajh.21552
  23. Mark T, Stern J, Furst JR, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant. 2008;14(7):795–8. doi: 10.1016/j.bbmt.2008.04.008. DOI: https://doi.org/10.1016/j.bbmt.2008.04.008
  24. Costa LJ, Miller AN, Alexander ET, et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant. 2011;46(4):523–8. doi: 10.1038/bmt.2010.170. DOI: https://doi.org/10.1038/bmt.2010.170
  25. DiPersio J., Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720–6. doi: 10.1182/blood-2008-08-174946. DOI: https://doi.org/10.1182/blood-2008-08-174946
  26. Покровская О.С. Механизм действия и клиническая эффективность антагониста хемокинового рецептора CXCR4 плериксафора при мобилизации гемопоэтических стволовых клеток. Клиническая онкогематология. 2012;5(4):371–9.
  27. [Pokrovskaya OS. Mechanism of action and clinical activity of CXCR4 antagonist Plerixafor in stem cell mobilization. Klinicheskaya onkogematologiya. 2012;5(4):371–9. (In Russ)]
  28. Кучер М.А., Моталкина М.С., Климова О.У. и др. Плериксафор у пациентов со сниженной мобилизационной способностью аутологичных гемопоэтических стволовых клеток. Клиническая онкогематология. 2016;9(2):155–61. doi: 10.21320/2500-2139-2016-9-2-155-61. DOI: https://doi.org/10.21320/2500-2139-2016-9-2-155-161
  29. [Kucher MA, Motalkina MS, Klimova OU, et al. Plerixafor in Patients with Decreased Mobilizing Ability of Autologous Hematopoietic Stem Cells. Clinical oncohematology. 2016;9(2):155–61. doi: 10.21320/2500-2139-2016-9-2-155-61. (In Russ)]
  30. Levesque JP, Takamatsu Y, Nilsson SK, et al. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood. 2001;98(5):1289–97. doi: 10.1182/blood.V98.5.1289. DOI: https://doi.org/10.1182/blood.V98.5.1289
  31. Levesque JP, Hendy J, Takamatsu Y, et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest. 2003;111(2):187–96. doi: 10.1172/jci15994. DOI: https://doi.org/10.1172/JCI200315994
  32. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and upregulating CXCR4. Nat Immunol. 2002;3(7):687–94. doi: 10.1038/ni813. DOI: https://doi.org/10.1038/ni813
  33. Cesana C, Carlo-Stella C, Regazzi E, et al. CD34+ cells mobilized by cyclophosphamide and granulocyte colonystimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. Bone Marrow Transplant. 1998;21(6):561–8. doi: 10.1038/sj.bmt.1701133. DOI: https://doi.org/10.1038/sj.bmt.1701133
  34. Bruns I, Steidl U, Fischer JC, et al. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica. 2008;93(3):347–55. doi: 10.3324/haematol.12081. DOI: https://doi.org/10.3324/haematol.12081
  35. Kim MG, Han N, Lee EK, Kim T. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis. Bone Marrow Transplant. 2015;50(4):523–30. doi: 10.1038/bmt.2014.297. DOI: https://doi.org/10.1038/bmt.2014.297
  36. Tuchman SA, Bacon WA, Huang LW, et al. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. J Clin Apher. 2015;30(3):176–82. doi: 10.1002/jca.21360. DOI: https://doi.org/10.1002/jca.21360
  37. Dingli D, Nowakowski GS, Dispenzieri A, et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma. 2006;6(5):384–8. doi: 10.3816/clm.2006.n.014. DOI: https://doi.org/10.3816/CLM.2006.n.014
  38. Hamadani M, Kochuparambil ST, Osman S, et al. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol Blood Marrow Transplant. 2012;18(7):1128–35. doi: 10.1016/j.bbmt.2012.01.005. DOI: https://doi.org/10.1016/j.bbmt.2012.01.005
  39. Hiwase DK, Bollard G, Hiwase S. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy. 2007;9(6):539–47. doi: 10.1080/14653240701452800. DOI: https://doi.org/10.1080/14653240701452800
  40. Jantunen E, Putkonen M, Nousiainen T, Low-dose or intermediate-dose cyclophosphamide plus granulocyte colonystimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant. 2003; 31(5):347–51. doi: 10.1038/sj.bmt.1703840. DOI: https://doi.org/10.1038/sj.bmt.1703840
  41. Nazha A, Cook R, Vogl DT, et al. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Bone Marrow Transplant. 2011;46(1):59–63. doi: 10.1038/bmt.2010.63. DOI: https://doi.org/10.1038/bmt.2010.63
  42. Brioli A, Perrone G, Patriarca F, et al. Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. Bone Marrow Transplant. 2015;50(5):673–8. doi: 10.1038/bmt.2014.322. DOI: https://doi.org/10.1038/bmt.2014.322
  43. Samaras P, Pfrommer S, Seifert B, et al. Efficacy of vinorelbine plus granulocyte colonye-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma. Biol Blood Marrow Transplant. 2015;21(1):74–80. doi: 10.1016/j.bbmt.2014.09.020. DOI: https://doi.org/10.1016/j.bbmt.2014.09.020
  44. Heizmann M, O’Meara AC, Moosmann PR, et al. Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant lymphoma. Bone Marrow Transplant. 2009;44(2):75–9. doi: 10.1038/bmt.2008.434. DOI: https://doi.org/10.1038/bmt.2008.434
  45. Annunziata M, Celentano M, Pocali B, et al. Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma. Ann Hematol. 2006;85(6):394–9. doi: 10.1007/s00277-005-0058-0. DOI: https://doi.org/10.1007/s00277-005-0058-0
  46. Bargetzi MJ, Passweg J, Baertschi E, et al. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bone Marrow Transplant. 2003;31(2):99–103. doi: 10.1038/sj.bmt.1703787. DOI: https://doi.org/10.1038/sj.bmt.1703787
  47. Schmid A, Friess D, Taleghani BM, et al. Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). Leuk Lymphoma. 2015;56(3):608–14. doi: 10.3109/10428194.2014.927454. DOI: https://doi.org/10.3109/10428194.2014.927454
  48. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99(3):731–5. doi: 10.1182/blood.v99.3.731. DOI: https://doi.org/10.1182/blood.V99.3.731
  49. Palumbo A, Bringhen S, Bruno B, et al. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood. 2010;115(10):1873–9. doi: 10.1182/blood-2010-08-301085. DOI: https://doi.org/10.1182/blood-2009-09-241737
  50. Giralt S. 200mg/m2 melphalan – the gold standard for multiple myeloma. Nat Rev. 2010;7(9):490–1. doi: 10.1038/nrclinonc.2010.104. DOI: https://doi.org/10.1038/nrclinonc.2010.104
  51. Philips GL, Meisenberg BR, Reece DE, et al. Activity of single-agent melphalan 220 to 300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant. 2004;33(8):781–7. doi: 10.1038/sj.bmt.1704424. DOI: https://doi.org/10.1038/sj.bmt.1704424
  52. Moreau P, Milpied N, Mahe B. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant. 1999;23(10):1003–6. doi: 10.1038/sj.bmt.1701763. DOI: https://doi.org/10.1038/sj.bmt.1701763
  53. Reece D., Song K., Leblanc R., et al. Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma. Oncologist. 2013;18:611–8. doi: 10.1634/theoncologist.2012-0384. DOI: https://doi.org/10.1634/theoncologist.2012-0384
  54. Roussel M, Moreau P, Huynh A, et al. Bortezomib ad high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood. 2010;115(1):32–7. doi: 10.1182/blood-2009-06-229658. DOI: https://doi.org/10.1182/blood-2009-06-229658
  55. Nishihori T, Alekshun TJ, Shain K, et al. Bortezomib salvage followed by a phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Br J Haematol. 2012;157(5):553–63. doi: 10.1111/j.1365-2141.2012.09099.x. DOI: https://doi.org/10.1111/j.1365-2141.2012.09099.x
  56. Huang W, Li J, Li H, et al. High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy. Leuk Lymphoma. 2012;53(12):2507–10. doi: 10.3109/10428194.2012.685735. DOI: https://doi.org/10.3109/10428194.2012.685735
  57. Mark TM, Reid W, Niesvizky R, et al. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplant in multiple myeloma. Biol Blood Marrow Transplant. 2013;19(5):831–7. doi: 10.3109/10428194.2012.685735. DOI: https://doi.org/10.1016/j.bbmt.2013.02.013
  58. Martino M, Tripepi G, Messina G, et al. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. Bone Marrow Transplant. 2016;51(9):1197–203. doi: 10.1038/bmt.2016.94. DOI: https://doi.org/10.1038/bmt.2016.94
  59. Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118(12):3419–25. doi: 10.1182/blood-2011-04-351924. DOI: https://doi.org/10.1182/blood-2011-04-351924
  60. Veeraputhiran M, Jain T, Deol A, et al. BEAM conditioning regimen has higher toxicity compared with high-dose melphalan for salvage autologous hematopoietic stem cell transplantation in multiple myeloma. Clin Lymph Myeloma Leuk. 2015;15(9):531–5. doi: 10.1016/j.clml.2015.05.008. DOI: https://doi.org/10.1016/j.clml.2015.05.008
  61. Abu Zaid B, Abdul-Hai A, Grotto I, et al. Autologous transplant in multiple myeloma with an augmented conditioning protocol. Leuk Lymphoma. 2013;54(11):2480–4. doi: 10.3109/10428194.2013.782608. DOI: https://doi.org/10.3109/10428194.2013.782608
  62. Musso M, Messina G, Marcacci G, et al. High-dose melphalan plus thiotepa as conditioning regimen before second autologous stem cell transplantation for “de novo” multiple myeloma patients: a phase II study. Biol Blood Marrow Transplant. 2015;21(11):1932–8. doi: 10.1016/j.bbmt.2015.06.011. DOI: https://doi.org/10.1016/j.bbmt.2015.06.011

Keywords:

multiple myeloma, autologous hematopoietic stem cell transplantation, mobilization regimen, conditioning regimen

License

Copyright (c) 2017 Clinical Oncohematology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

For Contact

  • Sergei Vasil’evich Gritsaev, DSci, Russian Scientific Research Institute of Hematology and Transfusiology under the Federal Medico-Biological Agency, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024, ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии ФМБА», 2-я Советская ул., д. 16, Санкт-Петербург, Российская Федерация, 191024, e-mail: gritsaevsv@mail.ru
2017-1

Downloads

Published

01.01.2017

Issue

Vol. 10 No. 1 (2017)
REVIEWS

How to Cite

Gritsaev S.V., Kuzyaeva A.A., Bessmel’tsev S.S. Certain Aspects of Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma. Clinical Oncohematology. Basic Research and Clinical Practice. 2017;10(1):7–12. doi:10.21320/2500-2139-2017-10-1-7-12.

Most read articles by the same author(s)